Printer Friendly

Hepatitis C infection: a clinical review.

Abstract: Nearly three million persons in the United States are viremic with hepatitis C (HCV). Despite a decreasing incidence of HCV in this country, the prevalence of HCV-related chronic liver disease is increasing. Most infections in the United States are acquired by intravenous drug use. The chronicity rate of HCV is high, reaching 85% in some populations, and the risk of progression to advanced liver disease is as high as 20% within twenty years of infection. Host factors like alcohol use accelerate the rate of progression. The enzyme immunoassay is the preferred initial test for diagnosis; the third generation assay has greater than a 99% specificity in immunocompetent patients. Barring contraindications, the standard of care for treatment of chronic HCV has become pegylated interferon and ribavirin. With this therapy, the cure rate for treatment-naive patients is about 55%, but rates are higher in certain groups. Common side effects of therapy include neuropsychiatric symptoms, influenza-like symptoms and hematological abnormalities.

Key Words: hepatitis C, liver disease, pegylated interferon, ribavirin

**********

The Virus and its Epidemiology

Originally identified in 1989, hepatitis C (HCV) has become the most important cause of "non-A, non-B" hepatitis. (1) HCV is an RNA virus belonging to the Flaviviridae family. Its genetic code differs substantially among its six genotypes and ninety or more subtypes, with two genotypes having as much as a 34% nucleotide sequence disparity. (2) This genetic heterogeneity may in part explain the difficulty in developing an effective HCV vaccine. (3)

Based on the National Health and Nutrition Examination Survey (NHANES III), it is estimated that 2.7 million Americans are viremic with HCV, and nearly 4 million have the HCV antibody. (4) These numbers are likely underestimates, because groups with high HCV prevalence rates, such as the mentally ill and the incarcerated, were excluded from the survey. According to one Justice Department study, some 1.3 to 1.4 million inmates released from prison in 1996 were infected with hepatitis C. (5) Persons between the ages of 40 to 59 currently have the highest prevalence of HCV infection. (4)

The incidence of acute HCV is approximately 35,000 cases per year, which represents a decline since the late 1980s. (6) Despite the decrease in incidence, HCV is the most common chronic blood-borne pathogen in the United States. (7) Because of a significant lag time between infection onset and hepatic manifestations, the prevalence of HCV-related liver disease is actually increasing. A fourfold increase in the number of adults diagnosed with chronic HCV is expected to occur from 1990 to 2015, (7) and HCV liver-related deaths are expected to nearly triple by the year 2020. (8)

Most HCV-infected patients in the United States acquire the virus by intravenous (IV) drug use; the seroprevalence of hepatitis C in this population is greater than 75%. (9) Some patients acquired the infection from transfusion, but this has become rare following the advent in 1992 of routine HCV testing of the US blood supply. Other routes of transmission include high-risk sexual behavior, occupational exposure, unsafe medical practices, infected donor organs from transplant, and maternal-infant transmission (10,11) (Fig. 1).

Although HCV can be acquired sexually, transmission rates are low. (12-14) Studies examining sexual transmission in monogamous couples often reveal confounding factors for transmission, such as shared parenteral exposures. (15,16) Yet significant nucleotide sequence homology of the virus's RNA from infected monogamous couples without other risk factors suggests the occurrence of interspousal transmission. (17) Sexual promiscuity increases the risk of HCV acquisition, (10,18) and human immunodeficiency virus (HIV) coinfection further increases the likelihood of sexual transmission. (18,19)

[FIGURE 1 OMITTED]

Regarding vertical transmission (mother to infant), rates ranged from 3.3 to 6.4% in two prospective studies of HCV RNA-positive women. (20,21) A correlation exists between high maternal titers of HCV RNA and the probability of infecting the infant. (20,22,23) The risk is also increased if the mother was previously or is currently using drugs intravenously, or is coinfected with HIV. (24-27) In an analysis of eight studies of HIV coinfected women, the weighted risk of maternal-infant transmission was over 20%, versus 8% for HIV-negative mothers. (28) Although HCV RNA is sometimes detectable in amniotic fluid, (29) it is not known if mother-to-infant transmission occurs in utero or at the time of delivery.

Natural History

The first detectable biochemical marker of HCV infection is the presence of HCV RNA, which can be found as early as one week after exposure. (30) Elevation of serum alanine aminotransferase (ALT) levels, reflecting hepatocyte damage, may be seen within 4 to 12 weeks on average. (31) Because 30 to 50% of patients have no detectable antibodies by enzyme immunoassay in early infection, (32,33) antibody testing is unreliable in acute HCV. And although 90% of patients develop HCV antibodies within 12 weeks of infection, some may take over a year to seroconvert. (32) Only about one-third of acute HCV patients have symptoms, which may include fatigue, anorexia, myalgias, arthralgias, jaundice, or right upper quadrant pain. (31,34) Fulminant hepatic failure from HCV is rare. (35,36)

Although some studies of young women and children have reported low rates of chronic HCV viremia (55%), (37,38) prospective studies in more diverse populations have confirmed up to an 85% chronicity rate. (39) Thus, 15 to 45% of patients with acute hepatitis C will experience spontaneous recovery. Aside from younger age and female sex, certain HLA alleles are associated with spontaneous clearance of viremia. (40,41) Those with jaundice or symptoms of acute infection are more likely to clear the virus than acutely infected individuals who are asymptomatic. (42) However, black persons less frequently clear HCV spontaneously. (43) In general, HCV's high rate of chronicity may be related to the virus's high likelihood of mutation and the lack of, or failure to maintain, a vigorous T-lymphocyte response to infection. (31,44,45)

Chronic HCV has been associated with a myriad of extrahepatic conditions. Yet studies linking these conditions to HCV are limited by small sample size, lack of control groups, and retrospective analysis. Nevertheless, in a prospective multicenter study of 321 chronically infected HCV patients, at least one extrahepatic manifestation was present in 38% of patients; 19% had rheumatic symptoms, and 17% had cutaneous problems. (46) In a hospital-based case control study from the Veterans Affairs Hospitals, HCV was significantly associated with porphyria cutanea tarda, vitiligo, lichen planus, cryoglobulinemia, membranoproliferative glomerulonephritis, and non-Hodgkin's lymphoma. (47) Monoclonal gammopathy may also be associated with HCV. In a study of 239 HCV patients, monoclonal bands were detected in 11% of patients compared with 1% of an age-matched control population. (48) Finally, cognitive problems may be more common in chronic HCV patients, even in the absence of clinically significant liver disease or interferon-based therapy. (49,50)

The rate of hepatitis C patients' progression to fibrosis or cirrhosis has been a controversial subject. Cirrhosis rates as high as 50% have been described in cross-sectional studies from liver clinics, (51) although selection bias may have inflated these figures. Estimates of progression after 20 years of chronic HCV infection in prospective analyses range from about 2% in young women in community-based studies (18) to about 20% in middle-aged patients in post-transfusion studies. (52) Although there is generally no correlation between viral factors like genotype and disease progression, (53) host factors contribute strongly to the increased risk of progressive liver disease. Duration of infection, (54) male gender, older age at time of infection, (55) and coinfection with human immunodeficiency virus (56) or hepatitis B (HBV) (57) are all associated with progression of HCV-related liver disease. Coinfection with schistosomes, (58) iron overload, (59) obesity, (60) and coexisting nonalcoholic fatty liver (61) may contribute to the rapidity of HCV progression. Alcohol can also accelerate liver injury, even in small amounts (less than 140 g per week). (62) In fact, alcohol may actually enhance HCV replication. (63)

Once cirrhosis develops, hepatocellular carcinoma (HCC) develops at a rate of about 2% per year (64) (Fig. 2). The risk factors for the development of HCC are similar to those for progression of HCV-related liver disease. (65-68) In the United States, HCV is the most common indication for liver transplantation. (69) Although about 25% of all HCC diagnosed in this country is HCV-related, death from chronic HCV in the United States is more likely to result from end-stage liver disease than from HCC. (70,71)

[FIGURE 2 OMITTED]

Tests for diagnosis, monitoring, and screening

Serum ALT is a readily available and inexpensive test to monitor HCV disease activity. However, a weak correlation exists between the severity of histolysis on liver biopsy and serum ALT levels. (72,73) Furthermore, ALT levels may fluctuate; consequently, a single value in the normal range can neither rule out active infection (74) nor help gauge the severity of underlying liver disease. (75,76) A patient with an initially normal ALT level with confirmed HCV viremia should undergo repeat testing over several months to confirm a persistently normal ALT. Although early normalization of an abnormal ALT level may indicate response to antiviral treatment, (77-79) a decrease or absence of HCV RNA is the most reliable marker to assess the success of therapy.

The preferred screening test and initial test for HCV diagnosis is the enzyme immunoassay (EIA). EIAs detect mixtures of antibodies directed against various HCV antigens including those from the viral core (C), and from nonstructural viral regions 3 and 4 (NS3 and NS4). (80) The third generation EIA detects an additional antigen from the nonstructural region 5 (NS5) and has a very high sensitivity and a specificity greater than 99% in immunocompetent patients. (81) A negative EIA excludes chronic HCV in patients with normal immune systems. Both second and third generation EIAs are commercially available in the U.S.

The development of antibodies against HCV may be impaired in patients on hemodialysis and in those who are profoundly immunodeficient. Conversely, patients with autoimmune diseases may show false positive results. (82,83) In these patient groups, RNA testing should be utilized for diagnosis (Fig. 3). The recombinant immunoblot assay (RIBA) detects similar antigens to those detected by EIA; however, it is technically more demanding and more expensive. The RIBA has been used to confirm positive EIA results in low risk individuals. Yet, given the high sensitivity and specificity of EIA, clinical RIBA testing is essentially obsolete. (84)

[FIGURE 3 OMITTED]

Detection of HCV RNA is important to confirm the diagnosis of active HCV replication and to assess eradication of virus after treatment. To confirm viremia a qualitative RNA assay is recommended. A repeat test should be obtained if the results are negative, since a single negative assay does not exclude HCV replication. On the other hand, a single positive test result affirms active HCV replication. The lower limits of detection for the qualitative test by polymerase chain reaction (PCR) is 50 IU/ml. (85) An alternative test for qualitative HCV RNA detection is the transcription-mediated nucleic acid amplification assay (TMA), which demonstrates comparable specificity and improved sensitivity compared with the PCR assay; it detects as little as 5 IU/mL RNA. (86)

The most important use for the quantitative virologic assays is for monitoring response to treatment. Quantitative HCV assays include PCR and branched chain DNA methods. Regardless of method chosen, it is advisable to use a single method for longitudinal viral load monitoring, because results are not comparable between assays. Moreover, variations of 1 to 2 log units can occur with any assay, so important clinical decisions should not be based on a single RNA determination. (87) The viral load does not predict the likelihood of disease progression or the degree or hepatic injury, (72) but gives prognostic information about treatment. (88,89)

A new enzyme immunoassay capable of quantifying total HCV core antigen has been developed. The HCV core antigen can be used as a marker of viral replication. (90) Preliminary studies show the new assay correlates well with commercially available HCV quantitative RNA tests. (91) However, total HCV core antigen testing is not yet FDA approved.

In attempts to predict HCV disease severity, many authors have analyzed the use of common laboratory tests or serum markers of inflammation and fibrosis. Although an aspartate aminotransferase to alanine aminotransferase (AST/ALT) ratio of one or more was useful to diagnose cirrhosis in some studies, (92-94) the ratio failed to predict advanced disease in other studies. (95,96) Nonetheless, the AST/ALT ratio may provide prognostic information in HCV cirrhotic patients that is comparable to that provided by established prognostic scores like Child-Pugh. (94) Products of collagen synthesis and extracellular matrix components like hyaluronic acid have also been investigated, but positive predictive value for cirrhosis is poor. (97) A panel of biomarkers comprised of apolipoprotein A1, haptoglobin, [alpha]-2 macroglobulin, [gamma]-glutamyl transpeptidase (GGT), and total bilirubin appears promising as a surrogate predictor of significant fibrosis. (98) Unfortunately, no single or group of laboratory tests have been well-validated for disease severity prediction in the general HCV population.

Since noninvasive methods are not reliable for determining the activity of HCV-related liver disease, liver biopsy is necessary in most HCV cases. Despite biopsy drawbacks like sampling error and potential complications, histologic analysis is the only reliable predictor of disease progression and prognosis; cirrhosis develops within ten years in nearly all patients with high-grade necroinflammation on liver biopsy. (99) Liver biopsy may also assist in prognostication by providing additional information about steatosis, iron content, and concomitant alcohol use. (100) Finally, information gleaned from the liver biopsy allows patients and their physicians to make better choices with respect to deferring treatment in those with favorable prognoses. In those patients deferring therapy, an initial biopsy can serve as a baseline against which future biopsies could be compared. However, there is no data to suggest an optimal interval in which to rebiopsy.

Despite a paucity of evidence supporting it, semiannual screening for HCC with hepatic ultrasound and alfa-fetoprotein (AFP) is commonly performed in the United States. Only one prospective study from China showed this screening protocol prolonged survival in high risk patients. (101) Although ultrasound has high specificity, (102) it can still detect focal liver lesions other than HCC, (103) sometimes leading to unnecessary invasive testing. Furthermore, AFP misses many HCCs and may inappropriately arouse suspicion of cancer in many patients. (104) If utilized, HCC screening should only be performed in cirrhotic patients, since HCC is rare in those with less advanced stages of liver disease. (70)

Treatment

The absence of detectable serum HCV RNA by qualitative PCR (<50 IU/mL) 24 weeks after completion of therapy, what is known as sustained virologic response (SVR), is the standard measure of a favorable response to treatment; those treated who achieve SVR have a favorable long-term histologic and clinical outcome. (105) However, SVR is a surrogate endpoint, and attaining it has never been well-correlated with improved survival. (106) Nonetheless, the rates of SVR have improved with enhancements in therapy.

The introduction of pegylated interferon has been the most important recent advance in chronic HCV therapy. Covalently bonding a polyethylene glycol (PEG) moiety to an interferon (IFN) molecule backbone enhances interferon's biologic activity and prolongs its half-life. (107) In fact, the standard of care for treatment of chronic HCV for genotype one (approximately 70% of U.S. isolates) (108) has become pegylated interferon (PEG-IFN) and ribavirin, barring contraindications.

Although 48 weeks of treatment with standard interferon with ribavirin resulted in SVR rates as high as 43%, (89) 48 weeks of PEG-IFN with ribavirin increased the sustained response rates to 54 to 56%, as shown in two large, international, randomized, controlled studies, one using PEG-IFN alfa-2b and the other using PEG-IFN alfa-2a. (109,110) In both trials, sustained response rates were significantly higher in the patients with lower baseline HCV RNA levels (under 2 million copies/mL or under 600,000 IU/ml), lesser degrees of fibrosis on pretreatment liver biopsies, lower body weight (under 75 kg), and genotypes two and three.

Treatment is most often recommended for those chronic hepatitis C patients who are at increased risk for progression to cirrhosis, such as those patients with HCV viremia (detectable HCV RNA), elevated aminotransferase levels, and at least moderate inflammation or portal fibrosis on liver biopsy. (111) However, many patients do not fit into the above profile (mild liver disease, persistently normal ALT, etc), and their treatment has been controversial. Therapy for these patients is considered on an individual basis, and details of their treatment are beyond the scope of this article. Nonetheless, more than half of patients with HCV in certain populations are not considered candidates for therapy. The most frequent reasons for exclusion are current alcohol or substance abuse, severe psychiatric illness, and comorbidities like autoimmune or renal disease. (112-114)

Even when patients are offered therapy, an important obstacle to successful treatment is medication intolerability. A critical component of treatment is patient education about potential side effects, and regular follow-up visits during therapy are essential to encourage adherence and to detect adverse effects early.

Side effects of IFN-based combination therapy can be grouped broadly into influenza-like symptoms, neuropsychiatric symptoms, and hematologic abnormalities. In large treatment trials, adverse events prompted therapy discontinuation in 10 to 14% of patients and dose reductions in 32 to 42%. Mild injection site reactions, dose reductions due to cytopenias, and increased flu-like symptoms (in one study), were more common in the pegylated-interferon combination arms compared with the standard interferon combination arms, but the differences were small. (109,110)

Depression can occur in up to one-third of patients on therapy, (109) and many practitioners are treating mild to moderate depression with selective serotonin reuptake inhibitors and other antidepressants. Prophylactic paroxetine has been shown to minimize depression induced by high-dose IFN alfa-2b in melanoma patients. (115) In a more recent prospective trial, nearly 80% of HCV patients developing interferon-induced depression were able to complete therapy successfully when treated concomitantly with paroxetine. (116)

For patients developing significant therapy-related cytopenias, hematopoietic growth factors have become increasingly popular as a means to complete therapy and to prevent both IFN and ribavirin dose reductions. In a prospective, open-label study of HCV-infected patients developing ribavirin-related anemia, patients receiving weekly epoetin alfa had increased hemoglobin levels and maintained ribavirin dosing compared with those patients receiving dose reductions only. (117) In one placebo-controlled study,

(118) HCV patients on treatment using adjunctive epoetin alfa had significantly impoved quality of life scores relative to IFN-treated patients using placebo. Nevertheless, there is currently no evidence that growth factors increase the likelihood of patients achieving SVR. Furthermore, hematopoietic growth factors may be cost-prohibitive.

Prevention and Vaccination

The 2002 National Institutes of Health Consensus Development Panel on Hepatitis C supports methadone treatment programs, needle and syringe exchange programs, and comprehensive education programs for IV drug users as potentially useful means to prevent the spread of the virus. (119) Syringe exchange is independently associated with the cessation of syringe sharing. (120,121) Although some studies suggest that syringe exchange programs can reduce the risk of HCV among IV drug users, the data are not consistent. (122,123)

Regarding the prevention of sexual transmission, the CDC affirms that partners serodiscordant for HCV in monogamous couples need not use condoms. (124) However, if monogamous couples wish to decrease an already low risk of transmission (0.03-0.6% per year; average 0.3% per year), (125) condoms could be used. On the other hand, the use of condoms is advised for infected patients with multiple or short-term sexual partners; sexual promiscuity increases the risk of acquiring HCV. (10,18)

No prospective studies have evaluated the use of cesarean section to prevent HCV transmission from infected mothers to their infants, and there are no data supporting antiviral therapy to prevent vertical transmission. In fact, interferons and ribavirin are contraindicated in pregnancy.

Preventing transmission from healthcare workers to patients has been controversial. Although transmission has been documented, it is rare and limited to case reports. (126-129) Up to half of the reports were confounded by other factors like contamination of patients' narcotics used for healthcare workers' surreptitious habit of IV drug use. (11) The calculated risk for HCV transmission from an RNA-positive surgeon to a patient during an invasive procedure is 0.00018%, which was roughly comparable to the chance of acquiring HCV by transfusion in the United States in the year 2000. (130) The 2002 NIH Consensus Development Panel on the Management of Hepatitis C recommends that no HCV-infected healthcare professional be restricted from his or her work. (119) Despite this recommendation, some health departments have required HCV-infected physicians to obtain informed consent before performing surgery on their patients. (131)

Finally, there is no evidence that casual or household contact with HCV-infected individuals increases the risk of acquiring infection. (132,133) Sharing household items like razors and toothbrushes should be avoided, however.

The CDC recommends that all patients with chronic HCV be vaccinated against hepatitis A and against hepatitis B, if at risk. (124) The recommendations may be based, in part, on a study of 432 patients with HCV who were prospectively followed for 7 years. Of 17 study patients who developed superinfection with hepatitis A, 7 patients developed fulminant hepatic failure, six of whom died. (134) This is a particularly significant rate of morbidity, since monoinfected patients (hepatitis A) develop fulminant hepatic failure in less than one percent of cases. (135,136) Vaccinating HCV patients who are seronegative for hepatitis A has been shown to be cost-effective relative to vaccinating without first checking antibody status or not vaccinating at all. (137) Cost-effectiveness is most favorable for younger patients. (138)

Less supportive evidence exists for recommending hepatitis B vaccination; although, as noted previously, patients with HCV and HBV coinfection may have a higher risk of cirrhosis compared with those monoinfected. (57) No cost analysis on HBV vaccination for HCV patients has been performed.

Acknowledgments

The author would like to thank Tara Douglas-Williams and Claire Campbell in Atlanta Medical Center's Library for their indefatigable efforts in finding his articles.
I Good people are good because they've come to wisdom through failure.
We get very little wisdom from success, you know.
--William Saroyan


Accepted January 15, 2004.

Copyright [c] 2004 by The Southern Medical Association

0038-4348/04/9704-0365

References

1. Choo QL, Weiner AJ, Overby LR, et al. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 1989;244:359-62.

2. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-83.

3. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-15399.

4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999;341:556-562.

5. National Commission on Correctional Health Care, National Institute of Justice (2002). The health status of soon-to-be released inmates. Washington DC: United States Department of Justice.

6. Alter MJ, Margolis HS. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(RR-19):1.

7. Kim WR. The burden of hepatitis C in the US. Hepatology 2002;36:S30-S34.

8. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant 2003;9:331-338.

9. Garfein RS, Vlahou D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-661.

10. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.

11. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36:S93-S98.

12. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-1205.

13. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males. Blood 1992;80:540-543.

14. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-1211.

15. Zylberberg H, Thiers V, Lagorce D, et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999;45:112-116.

16. Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001;96:3138-3141.

17. Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 1995;22:431-439.

18. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted disease clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-775.

19. Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993;12:827-831.

20. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001;170:103-106.

21. Healy CM, Cafferkey MT, Conroy A, et al. Outcome of infants born to hepatitis C infected women. Ir J Med Sci 2001;170:103-106.

22. Matubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: a prospective study. Eur J Pediatr 1995;154:973-978.

23. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-750.

24. Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995;84:251-255.

25. Paccagnini S, Prinicipi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995;14:195-199.

26. Zanetti AR, Tanzi E, Romano L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998;41:208-212.

27. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998;317:437-441.

28. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 34:223-229.

29. Delamare C, Carbonne B, Heim N, et al. Detection of hepatitis C virus RNA in amniotic fluid: a prospective study. J Hepatol 1999;31:416-420.

30. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.

31. Hoofnagle JH. The course and outcome of hepatitis C. Hepatology 2002;36:S21-S29.

32. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999;94:1183-1191.

33. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-644.

34. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1949-1950.

35. Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-634.

36. Mutimer D, Shaw J, Neuberger J, et al. Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A, non-B hepatitis. Gut 1995;36:433-436.

37. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.

38. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.

39. Shakil AO, Conry-Canilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337.

40. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999;354:2119-2124.

41. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatability complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113:1675-1681.

42. Gerlach JT, Diepolder HM, Zachoral R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.

43. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.

44. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-941.

45. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-344.

46. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C infection. Medicine 2000;79:47-56.

47. El-Serag H, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-1445.

48. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients in hepatitis C virus infection. Ann Intern Med 1998;129:294-298.

49. Hilsabeck R, Perry W, Hassanein T. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002;35:440-446.

50. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-39.

51. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med 1995;332:1463-1466.

52. DiBisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974.

53. Benvegnu L, Pontisso P, Cavalleto D, et al. Lack of correlation between hepatitis C genotypes and clinical course of hepatitis C virusrelated cirrhosis. Hepatology 1997;25:211-215.

54. Wong JB, Poynard T. The natural history of fibrosis in chronic hepatitis C. Hepatology. 2003;38(Supl. 1):182A.

55. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.

56. Soto B. Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.

57. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of the Hepatitis C Virus. Hepatology 1997;26:485-490.

58. Gad A, Tanaka E, Orii K, et al. Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. J Gastroenterol 2001;36:753-758.

59. Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000;47:220-225.

60. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97:2408-2414.

61. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.

62. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-1722.

63. Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003;38:57-65.

64. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-1316.

65. Kew MC, Mimi Cy, Kedda M, et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997;112:184-187.

66. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-183.

67. Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002;95:331-339.

68. Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993;88:39-43.

69. United Network for Organ Sharing. Organ Procurement and Transplant Network (OPTN) data as of March 1, 2002. Transplants by diagnosis: January 1991 to November 2001. Available at http://www.unos.org. Accessed on January 10, 2003.

70. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.

71. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83.

72. McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer. Am J Gastroenterol 1996;91:1516-1522.

73. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferase to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.

74. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995;22:413-417.

75. Inglesby TV, Rai R, Astemborski J, et al. A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999;29:590-596.

76. Pouti C, Magrini A, Statl T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997;26:1393-1398.

77. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:1225-1275.

78. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind, placebo controlled trial. N Engl J Med 1989;321:1506-1510.

79. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.

80. Alter HJ. New kid on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992:350-351.

81. Pawlotsky JM. Use and interpretation of virologic tests for hepatitis C. Hepatology 2002;36:S65-S73.

82. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-1136.

83. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody test to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993;168:1343-1348.

84. Pawlotsky JM. Critical issues in HCV: HCV diagnostics. 2004. Available at http://www.hivandhepatitis.com/essays/121503hcv.html. Accessed January 1, 2004.

85. Lee Sc, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-4179.

86. Ross RS, Viazov SO, Hoffmann S, et al. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitatitve detection of hepatitis C RNA. J Clin Lab Anal 2001;15:308-313.

87. Shiffman ML, Ferreira-Gonzalez A, Reddy KR, et al. Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003;98:1159-1166.

88. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;1485-1492.

89. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Interventional Therapy Group. Lancet 1998;352:1426-1432.

90. Bouier-Alias M, Patel K, Dahari H, et al. Clinical utility of total hepatitis C virus core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002;36:211-218.

91. Lunel F, Veillon P, Payan C. Evaluation of the ortho total HCV core antigen assay in comparison to methods of detection and quantification for HCV RNA. AASLD, Boston Ma, 2002;759A.

92. Sheth S, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 1998;93:44-48.

93. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44:1249-1253.

94. Gianni E, Risso D, Botta F, et al. Validity and clinical utility of the AST/ALT ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Int Med 2003;163:218-224.

95. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156-2159.

96. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000;95:2328-2332.

97. McHutchison JG, Blatt LM, deMedina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000;15:945-951.

98. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of pegylated interferon alfa-2b and ribavirin. Hepatology 2003;38:481-492.

99. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.

100. Serfaty L, Poujol-Robert A, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002;97:1807-1812.

101. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123:357-360.

102. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002;36(supl 1):S84-92.

103. Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002;97:397-405.

104. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alphafetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001;34:570-575.

105. Lau DT, Kleiner DE, Ghany MG, et al. Ten year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-1127.

106. Linday KL. Introduction to therapy of hepatitis C. Hepatology 2002;36:S114-S120.

107. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001;3:30-37.

108. Lau JY, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996;124:868-876.

109. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.

110. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.

111. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-909.

112. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002;34:268-271.

113. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.

114. Yawn BP, Wollan P, Gazzuola L, et al. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002;51:135-140.

115. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.

116. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-1099.

117. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin and interferon alfa. Am J Gastroenterol 2003;98:2491-2499.

118. Afdhal NH, Goon B, Smith K, et al. Epoetin-alfa improves and maintains helath-related quality of life in anemic HCV-infected patients receiving interferon/ribavirin: HRQL from the Proactive Study. Hepatology. 2003;38(supl 1):302-303A.

119. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Available at http://consensus.nih.gov. Accessed June 23, 2003.

120. Watters JK, Estilo MJ, Clark GL, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;12:115-120.

121. Blumenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange on high-risk injection drug users: a cohort study. AIDS 2000;14:605-611.

122. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among infection drug users in the Tacoma Syringe Exchange Program. Am J Public Health 1995;85:1531-1537.

123. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999;149:203-213.

124. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47:1-33.

125. Terrault NA. Sexual activity as a risk factor for hepatitis C infection. Hepatology 2002;36:S99-S105.

126. Cody SH, Nainan OV, Garfein RS, et al. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med 2002;162:345-350.

127. Ross RS, Viazou S, Gross T, et al. Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med 2000;343:1851-1854.

128. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-560.

129. Duckworth GJ, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. Commun Dis Public Health 1999;2:188-192.

130. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch Intern Med 2000;160:2313-2316.

131. Associated Press. Hepatitis-infected surgeon must get consent. State directive says consent necessary before operating. Available at http://www.wnbc.com. Accessed April 19, 2002.

132. Everhart JE, DiBisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990;112:544-545.

133. Hou CH, Chen WY, Kao JH, et al. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol 1995;45:381-385.

134. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290.

135. Papaeuangelou G, Lassopoulous N, Roumeliotou-Karayannis A, et al. Etiology of fulminant viral hepatitis in Greece. Hepatology 1984;4:369-372.

136. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-1872.

137. Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002;97:721-728.

138. Jacobs RJ, Koss RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002;97:427-434.

RELATED ARTICLE: Key Points

* It is reported that almost three million Americans are chronically infected with hepatitis C, but this figure could be a substantial underestimate.

* The preferred screening test and initial test for hepatitis C is the enzyme immunoassay (EIA) which has a high sensitivity and specificity in immunocompetent patients.

* Viral load (HCV RNA) does not predict disease progression or severity of liver damage, but does give prognostic information about treatment.

* The best therapy available for treatment-naive patients is pegylated interferon in combination with ribavirin.

* Vaccination against hepatitis A and B is essential for all HCV-infected patients who are not already immune to these viruses.

Brian L. Pearlman, MD

From the Center for Hepatitis C, Atlanta Medical Center, Atlanta, GA, and the Medical College of Georgia, Augusta, GA

Dr. Pearlman is on the speakers' bureau for Schering-Plough, the company that manufactures one of the two available pegylated interferon products to treat hepatitis C.

Reprint requests to Brian Pearlman, MD, Center for Hepatitis C, Atlanta Medical Center, 315 Boulevard NE, Suite 140, Atlanta, Georgia 30312. Email: brianpearlman@hotmail.com
COPYRIGHT 2004 Southern Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Review Article
Author:Pearlman, Brian L.
Publication:Southern Medical Journal
Date:Apr 1, 2004
Words:7727
Previous Article:Southern Medical Journal CME Topic: hepatitis C infection.
Next Article:Smallpox vaccination in the early 19th century using live carriers: the travels of Francisco Xavier de Balmis.
Topics:


Related Articles
WHO reaffirms: it's not dirty needles, it's unsafe sex. (Environmental Intelligence).
Hepatitis coinfection: two major studies published.
Desquamative interstitial pneumonia and hepatitis C virus infection: a rare association.
Gast-3. Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection.
Dear reader.
Current challenges in hepatitis C.
Extrahepatic manifestations of hepatitis C.
Extrahepatic manifestations of hepatitis C.
MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.
Epstein Barr virus hepatitis: case series and review.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters